Comparative Pharmacology
Head-to-head clinical analysis: FORADIL versus MAXAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FORADIL versus MAXAIR.
FORADIL vs MAXAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Formoterol is a long-acting beta2-adrenergic receptor agonist (LABA) that relaxes bronchial smooth muscle by increasing intracellular cyclic AMP.
Beta-2 adrenergic receptor agonist; relaxes bronchial smooth muscle via increased intracellular cAMP.
Inhalation: 12 mcg twice daily (every 12 hours) via Foradil Aerolizer.
2 inhalations (340 mcg) via oral inhalation every 4-6 hours as needed for bronchospasm; not to exceed 12 inhalations per day.
None Documented
None Documented
Terminal half-life: 7-10 hours. Steady-state achieved within 3-5 days; clinical context: allows twice-daily dosing for bronchodilation.
3.5–4.0 hours; clinically, this supports dosing every 4–6 hours as needed.
Renal (60% as unchanged drug and metabolites) and fecal (40% as metabolites).
Renal excretion of unchanged drug accounts for approximately 90% of elimination; fecal excretion is minimal (<5%).
Category C
Category C
Bronchodilator
Bronchodilator